The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

gyrB  -  DNA gyrase subunit B

Streptococcus pneumoniae R6

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of gyrB


High impact information on gyrB

  • Furthermore, gyrB and parE double mutations increased the MICs of VRT-125853 and VRT-752586 significantly, providing evidence of dual targeting [3].
  • Novobiocin resistance-conferring mutations in S. aureus, H. influenzae, and S. pneumoniae were found in gyrB, and these mutants showed little or no cross-resistance to VRT-125853 or VRT-752586 and vice versa [3].
  • Mutations in gyrB were important for resistance to gatifloxacin but not moxifloxacin, and mutation of gyrA was associated with resistance to moxifloxacin but not gatifloxacin, suggesting differences in the drug-target interactions of the two 8-methoxyquinolones [4].
  • The average similarity between the species tested was 76.4% (69.7-100%) for dnaJ and 75.9 (70.1-98.7%) for gyrB [2].

Biological context of gyrB

  • The nucleotide sequences of the QRDRs of the parE and gyrB genes from the five low-level Cpr S. mitis isolates and from the NCTC 12261 type strain were also analyzed [5].

Associations of gyrB with chemical compounds

  • Two strains (requiring a ciprofloxacin MIC of 64 microg/ml) carried known quinolone resistance mutations in parC, parE, and gyrB, resulting in S79F, D435V, and E474K changes, respectively [6].


  1. Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Bast, D.J., de Azavedo, J.C., Tam, T.Y., Kilburn, L., Duncan, C., Mandell, L.A., Davidson, R.J., Low, D.E. Antimicrob. Agents Chemother. (2001) [Pubmed]
  2. dnaJ and gyrB gene sequence relationship among species and strains of genus Streptococcus. Itoh, Y., Kawamura, Y., Kasai, H., Shah, M.M., Nhung, P.H., Yamada, M., Sun, X., Koyana, T., Hayashi, M., Ohkusu, K., Ezaki, T. Syst. Appl. Microbiol. (2006) [Pubmed]
  3. Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds. Grossman, T.H., Bartels, D.J., Mullin, S., Gross, C.H., Parsons, J.D., Liao, Y., Grillot, A.L., Stamos, D., Olson, E.R., Charifson, P.S., Mani, N. Antimicrob. Agents Chemother. (2007) [Pubmed]
  4. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Weigel, L.M., Anderson, G.J., Facklam, R.R., Tenover, F.C. Antimicrob. Agents Chemother. (2001) [Pubmed]
  5. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. González, I., Georgiou, M., Alcaide, F., Balas, D., Liñares, J., de la Campa, A.G. Antimicrob. Agents Chemother. (1998) [Pubmed]
  6. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Heaton, V.J., Goldsmith, C.E., Ambler, J.E., Fisher, L.M. Antimicrob. Agents Chemother. (1999) [Pubmed]
WikiGenes - Universities